The Trendlines Group's Portfolio Company Limaca Medical Announces Exclusive U.S. Distribution Agreement with Global Medical Equipment Company

- *Trendlines holds approximately 38% in Limaca. This commercial agreement underscores Trendlines' portfolio strength and innovation in breakthrough medical companies.*
- *Founded and incubated by Trendlines, Limaca has developed an automated endoscopic biopsy solution Precision-GI™ for gastrointestinal cancer diagnosis*
- *This strategic distribution partnership enables nationwide access to Precision-GI™ motorized EUS biopsy and supports broader adoption in GI cancer diagnostics*

Misgav, Israel, 4 January 2026 — The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, today announced that its portfolio company Limaca Medical Ltd. (**"Limaca"**), a commercial-stage medical device company advancing automated endoscopic biopsy solutions for gastrointestinal cancer diagnosis, has entered into an exclusive U.S. distribution agreement with a global leader in endoscopy equipment. Under the agreement, the global medical company will serve as Limaca's exclusive U.S. distribution partner for its Precision-GI™ automated biopsy system.

The exclusive U.S. distribution agreement with a leading medical equipment company marks an important commercial step for Limaca, enabling the wider clinical rollout of Precision-GI™ through an established partner in the endoscopy market.

Precision-GI™ is a motorized, EUS-guided biopsy system engineered to collect intact, high-quality core tissue from pancreatic and other gastrointestinal lesions while minimizing blood contamination. The device has obtained FDA 510(k) clearance, Breakthrough Device Designation[1], and CMS Transitional Pass-Through (TPT) payment status[2], reflecting its potential to enhance diagnostic accuracy in patients with life-threatening cancers.

Pancreatic and other GI cancers continue to rank among the deadliest globally, with a significant proportion of patients diagnosed at advanced stages. In this context, achieving a definitive diagnosis on the initial procedure is essential for prompt and effective treatment. Precision-GI™ was designed to overcome existing procedural limitations by automating tissue sampling and consistently delivering high-quality core specimens suitable for both histopathological and molecular analysis.

---

[1] https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program
[2] The CMS Transitional Pass-Through (TPT) program provides extra Medicare payments for new, costly drugs, biologicals, and devices in hospital outpatient settings (HOPDs) and Ambulatory Surgical Centers (ASCs) for up to three years, helping patients access innovative technologies while CMS collects cost data to set standard rates. This supplemental reimbursement helps cover costs beyond standard Ambulatory Payment Classification (APC) rates, encouraging adoption of breakthrough treatments.

This agreement enhances Limaca's commercial footprint and market visibility in the United States and is expected to facilitate broader clinical adoption of automated EUS-guided biopsy, supported by the availability of TPT reimbursement.

"This agreement endorses the validation of the quality and commercial potential within the Trendlines portfolio," added Haim Brosh, CEO of Trendlines. "We are proud to support companies that not only deliver innovation but also create meaningful impact in healthcare."

About The Trendlines Group Ltd.
The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

----

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:
Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990